In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Summary

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.

Timeline

Start

2025-07-01

Primary completion

2027-12-31

Completion

2028-12-31

Drugs

Indications